CLENE INC (CLNN) Stock Price & Overview
NASDAQ:CLNN • US1856342019
Current stock price
The current stock price of CLNN is 6.1 USD. Today CLNN is up by 2.52%. In the past month the price increased by 40.78%. In the past year, price increased by 43.84%.
CLNN Key Statistics
- Market Cap
- 66.185M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.58
- Dividend Yield
- N/A
CLNN Stock Performance
CLNN Stock Chart
CLNN Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CLNN. When comparing the yearly performance of all stocks, CLNN is one of the better performing stocks in the market, outperforming 78.8% of all stocks.
CLNN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLNN. CLNN has a bad profitability rating. Also its financial health evaluation is rather negative.
CLNN Earnings
On November 13, 2025 CLNN reported an EPS of -0.85 and a revenue of 15.00K. The company missed EPS expectations (-43.68% surprise) and missed revenue expectations (-73.33% surprise).
CLNN Forecast & Estimates
12 analysts have analysed CLNN and the average price target is 32.64 USD. This implies a price increase of 435.08% is expected in the next year compared to the current price of 6.1.
For the next year, analysts expect an EPS growth of 59.54% and a revenue growth -57.73% for CLNN
CLNN Groups
Sector & Classification
CLNN Financial Highlights
Over the last trailing twelve months CLNN reported a non-GAAP Earnings per Share(EPS) of -3.58. The EPS increased by 32.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -136.69% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLNN Ownership
CLNN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.97 | 391.561B | ||
| AMGN | AMGEN INC | 15.86 | 197.434B | ||
| GILD | GILEAD SCIENCES INC | 16.35 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.95 | 118.403B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.24 | 80.021B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.63 | 42.294B | ||
| INSM | INSMED INC | N/A | 31.169B | ||
| NTRA | NATERA INC | N/A | 28.017B | ||
| BIIB | BIOGEN INC | 11.53 | 26.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.86 | 23.418B | ||
| MRNA | MODERNA INC | N/A | 21.054B | ||
| EXAS | EXACT SCIENCES CORP | 341.87 | 19.824B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.619B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLNN
Company Profile
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. The company is headquartered in Salt Lake City, Utah and currently employs 75 full-time employees. The company went IPO on 2018-08-27. The company specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
Company Info
IPO: 2018-08-27
CLENE INC
6550 South Millrock Drive, Suite G50
Salt Lake City UTAH 84121 US
CEO: Robert Etherington
Employees: 75
Phone: 18016769695
CLENE INC / CLNN FAQ
What does CLNN do?
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. The company is headquartered in Salt Lake City, Utah and currently employs 75 full-time employees. The company went IPO on 2018-08-27. The company specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
Can you provide the latest stock price for CLENE INC?
The current stock price of CLNN is 6.1 USD. The price increased by 2.52% in the last trading session.
Does CLNN stock pay dividends?
CLNN does not pay a dividend.
What is the ChartMill rating of CLENE INC stock?
CLNN has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is CLENE INC (CLNN) stock traded?
CLNN stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for CLENE INC?
CLENE INC (CLNN) operates in the Health Care sector and the Biotechnology industry.
Would investing in CLENE INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CLNN.